Natixis Advisors LLC Raises Stock Position in Cencora, Inc. $COR

Natixis Advisors LLC grew its stake in shares of Cencora, Inc. (NYSE:COR) by 1.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 164,229 shares of the company’s stock after acquiring an additional 2,632 shares during the period. Natixis Advisors LLC’s holdings in Cencora were worth $51,326,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its position in Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Cencora during the 3rd quarter worth $26,191,000. Acadian Asset Management LLC grew its position in shares of Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after buying an additional 232,539 shares in the last quarter. Mediolanum International Funds Ltd increased its stake in shares of Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after buying an additional 32,138 shares during the period. Finally, Advisors Asset Management Inc. raised its holdings in shares of Cencora by 40.3% in the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after acquiring an additional 4,973 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $361.80 on Tuesday. The stock’s 50-day moving average is $354.60 and its 200 day moving average is $337.09. Cencora, Inc. has a 1-year low of $251.94 and a 1-year high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The company has a market cap of $70.38 billion, a P/E ratio of 43.49, a PEG ratio of 1.67 and a beta of 0.68.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.73 earnings per share. Research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is 28.85%.

Analyst Ratings Changes

A number of research firms recently weighed in on COR. TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Robert W. Baird set a $415.00 price target on shares of Cencora in a report on Tuesday, January 13th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Evercore dropped their price objective on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average price target of $399.00.

Insider Buying and Selling

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,220 shares of company stock worth $5,282,867 in the last 90 days. 0.38% of the stock is owned by corporate insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.